MPLT · Nasdaq · CIK 0001770069

MapLight Therapeutics, Inc.

MapLight Therapeutics, Inc.’s most recent SEC filing in our snapshot is a Form 4 filed on Oct 16, 2026. Its EDGAR record lists 82 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
—
Net income, FY2025
-$161.2M
Form 4 filings on record, past 12 months
82

Company overview

Legal name (as filed)
MapLight Therapeutics, Inc.
Ticker
MPLT
SEC Central Index Key (CIK)
0001770069
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
REDWOOD CITY, CA
State or country of incorporation
DE
Fiscal year ends
December 31
SEC filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Position in SEC ticker list
#2974 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from MapLight Therapeutics, Inc.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
n/aFY2024n/aFY2025
Net income
-$77.6MFY2024-$161.2MFY2025
MPLT annual results
ItemFY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue——
Net income-$77.6M-$161.2M
Diluted EPS-$105.38-$18.56
Total assets$136.9M$479.5M
Cash and equivalents$38.3M$46.7M

XBRL tags used: netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

MPLT latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Mar 26, 202610-KAnnual report· period Dec 31, 2025Document · Index
Aug 13, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 13, 20268-KMaterial agreement; Results of operations; Unregistered equity sale; Regulation FD disclosure· period Aug 13, 2026Document · Index
Apr 29, 2026DEF 14ADefinitive proxy statement· period Jun 23, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about MapLight Therapeutics, Inc., by form type:

4 ×19144 ×10SCHEDULE 13D/A ×38-K ×2EFFECT ×1424B3 ×1S-1/A ×1S-1 ×1SCHEDULE 13G ×110-Q ×1
MPLT recent filings
FiledFormWhat it isOriginal
Oct 16, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 15, 2026Document · Index
Oct 16, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 15, 2026Document · Index
Oct 16, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 15, 2026Document · Index
Oct 16, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 15, 2026Document · Index
Oct 16, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 15, 2026Document · Index
Oct 16, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 15, 2026Document · Index
Oct 15, 2026144Notice of proposed sale of securitiesDocument · Index
Oct 15, 2026144Notice of proposed sale of securitiesDocument · Index
Oct 15, 2026144Notice of proposed sale of securitiesDocument · Index
Oct 15, 2026144Notice of proposed sale of securitiesDocument · Index
Oct 15, 2026144Notice of proposed sale of securitiesDocument · Index
Oct 15, 2026144Notice of proposed sale of securitiesDocument · Index
Oct 15, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 23, 2026EFFECTEFFECTDocument · Index
Sep 23, 2026424B3424B3Document · Index
Sep 18, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 16, 2026Document · Index
Sep 18, 2026S-1/ARegistration statement (IPO and other offerings)Document · Index
Sep 16, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 9, 2026S-1Registration statement (IPO and other offerings)Document · Index
Aug 20, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Aug 19, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 17, 2026Document · Index
Aug 19, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 17, 2026Document · Index
Aug 19, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 17, 2026Document · Index
Aug 19, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 17, 2026Document · Index
Aug 19, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 17, 2026Document · Index
Aug 19, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 17, 2026Document · Index
Aug 18, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 14, 2026Document · Index
Aug 18, 2026SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
Aug 13, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 13, 20268-KMaterial agreement; Results of operations; Unregistered equity sale; Regulation FD disclosure· period Aug 13, 2026Document · Index
Aug 4, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 3, 2026Document · Index
Aug 3, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 3, 2026SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
Jul 31, 2026SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
Jul 30, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 28, 2026Document · Index
Jul 30, 2026144Notice of proposed sale of securitiesDocument · Index
Jul 28, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 28, 2026Document · Index
Jul 27, 20268-KRegulation FD disclosure; Other events· period Jul 27, 2026Document · Index
Jul 20, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 15, 2026Document · Index
Jul 20, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 15, 2026Document · Index

Insider filing activity

82 Form 4 filings appear in MapLight Therapeutics, Inc.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations· Companies headquartered in California

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001770069 and XBRL company facts. MapLight Therapeutics, Inc. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.